|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DEK |
Gene summary for DEK |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DEK | Gene ID | 7913 |
| Gene name | DEK proto-oncogene | |
| Gene Alias | D6S231E | |
| Cytomap | 6p22.3 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | P35659 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7913 | DEK | GSM4909281 | Human | Breast | IDC | 1.38e-62 | 8.81e-01 | 0.21 |
| 7913 | DEK | GSM4909282 | Human | Breast | IDC | 2.90e-71 | 9.17e-01 | -0.0288 |
| 7913 | DEK | GSM4909285 | Human | Breast | IDC | 6.44e-22 | 5.03e-01 | 0.21 |
| 7913 | DEK | GSM4909286 | Human | Breast | IDC | 8.45e-17 | 4.33e-01 | 0.1081 |
| 7913 | DEK | GSM4909287 | Human | Breast | IDC | 7.86e-08 | 3.00e-01 | 0.2057 |
| 7913 | DEK | GSM4909288 | Human | Breast | IDC | 2.36e-11 | 2.97e-01 | 0.0988 |
| 7913 | DEK | GSM4909289 | Human | Breast | IDC | 2.55e-22 | 8.93e-01 | 0.1064 |
| 7913 | DEK | GSM4909293 | Human | Breast | IDC | 2.38e-05 | 2.17e-01 | 0.1581 |
| 7913 | DEK | GSM4909294 | Human | Breast | IDC | 2.76e-07 | -3.76e-01 | 0.2022 |
| 7913 | DEK | GSM4909296 | Human | Breast | IDC | 7.10e-11 | -3.20e-01 | 0.1524 |
| 7913 | DEK | GSM4909297 | Human | Breast | IDC | 1.91e-13 | -2.51e-01 | 0.1517 |
| 7913 | DEK | GSM4909298 | Human | Breast | IDC | 9.09e-04 | 2.08e-01 | 0.1551 |
| 7913 | DEK | GSM4909302 | Human | Breast | IDC | 1.62e-02 | -2.79e-01 | 0.1545 |
| 7913 | DEK | GSM4909311 | Human | Breast | IDC | 1.46e-31 | -3.46e-01 | 0.1534 |
| 7913 | DEK | GSM4909312 | Human | Breast | IDC | 1.83e-15 | 3.17e-02 | 0.1552 |
| 7913 | DEK | GSM4909313 | Human | Breast | IDC | 2.61e-02 | -1.37e-01 | 0.0391 |
| 7913 | DEK | GSM4909316 | Human | Breast | IDC | 3.23e-02 | -2.89e-01 | 0.21 |
| 7913 | DEK | GSM4909319 | Human | Breast | IDC | 6.96e-40 | -3.08e-01 | 0.1563 |
| 7913 | DEK | GSM4909320 | Human | Breast | IDC | 3.41e-08 | -2.13e-01 | 0.1575 |
| 7913 | DEK | GSM4909321 | Human | Breast | IDC | 4.35e-18 | -2.95e-01 | 0.1559 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00160329 | Breast | Precancer | viral process | 58/1080 | 415/18723 | 3.42e-10 | 3.16e-08 | 58 |
| GO:00190589 | Breast | Precancer | viral life cycle | 47/1080 | 317/18723 | 2.42e-09 | 1.99e-07 | 47 |
| GO:00190799 | Breast | Precancer | viral genome replication | 22/1080 | 131/18723 | 5.63e-06 | 1.66e-04 | 22 |
| GO:20010208 | Breast | Precancer | regulation of response to DNA damage stimulus | 24/1080 | 219/18723 | 1.93e-03 | 1.87e-02 | 24 |
| GO:001603214 | Breast | IDC | viral process | 75/1434 | 415/18723 | 1.98e-12 | 4.02e-10 | 75 |
| GO:001905814 | Breast | IDC | viral life cycle | 61/1434 | 317/18723 | 1.61e-11 | 2.77e-09 | 61 |
| GO:001907914 | Breast | IDC | viral genome replication | 32/1434 | 131/18723 | 2.82e-09 | 2.46e-07 | 32 |
| GO:200102013 | Breast | IDC | regulation of response to DNA damage stimulus | 30/1434 | 219/18723 | 1.36e-03 | 1.40e-02 | 30 |
| GO:001603224 | Breast | DCIS | viral process | 73/1390 | 415/18723 | 3.40e-12 | 6.88e-10 | 73 |
| GO:001905824 | Breast | DCIS | viral life cycle | 59/1390 | 317/18723 | 4.05e-11 | 5.74e-09 | 59 |
| GO:001907923 | Breast | DCIS | viral genome replication | 30/1390 | 131/18723 | 2.12e-08 | 1.45e-06 | 30 |
| GO:200102023 | Breast | DCIS | regulation of response to DNA damage stimulus | 30/1390 | 219/18723 | 8.32e-04 | 9.47e-03 | 30 |
| GO:0016032 | Colorectum | AD | viral process | 168/3918 | 415/18723 | 4.67e-20 | 3.66e-17 | 168 |
| GO:0019058 | Colorectum | AD | viral life cycle | 119/3918 | 317/18723 | 6.18e-12 | 8.23e-10 | 119 |
| GO:0051052 | Colorectum | AD | regulation of DNA metabolic process | 116/3918 | 359/18723 | 2.47e-07 | 1.00e-05 | 116 |
| GO:0019079 | Colorectum | AD | viral genome replication | 51/3918 | 131/18723 | 1.83e-06 | 5.51e-05 | 51 |
| GO:2001020 | Colorectum | AD | regulation of response to DNA damage stimulus | 71/3918 | 219/18723 | 4.38e-05 | 7.65e-04 | 71 |
| GO:0006325 | Colorectum | AD | chromatin organization | 119/3918 | 409/18723 | 4.85e-05 | 8.33e-04 | 119 |
| GO:0006282 | Colorectum | AD | regulation of DNA repair | 42/3918 | 130/18723 | 1.57e-03 | 1.32e-02 | 42 |
| GO:00160322 | Colorectum | MSS | viral process | 157/3467 | 415/18723 | 7.94e-21 | 6.19e-18 | 157 |
| Page: 1 2 3 4 5 6 7 8 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DEK | SNV | Missense_Mutation | c.904G>A | p.Glu302Lys | p.E302K | P35659 | protein_coding | tolerated(0.26) | benign(0.112) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| DEK | SNV | Missense_Mutation | c.700N>A | p.Glu234Lys | p.E234K | P35659 | protein_coding | tolerated(0.08) | probably_damaging(0.98) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DEK | insertion | Nonsense_Mutation | novel | c.949_950insTTCTGCTTCTTTAAACTAACATAAACTAAGGATACATCAAT | p.Lys317IlefsTer5 | p.K317Ifs*5 | P35659 | protein_coding | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| DEK | SNV | Missense_Mutation | c.904G>C | p.Glu302Gln | p.E302Q | P35659 | protein_coding | tolerated(0.16) | benign(0.249) | TCGA-C5-A1BM-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DEK | SNV | Missense_Mutation | novel | c.1081N>A | p.Glu361Lys | p.E361K | P35659 | protein_coding | tolerated(0.29) | possibly_damaging(0.83) | TCGA-C5-A7CK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| DEK | SNV | Missense_Mutation | c.476G>A | p.Ser159Asn | p.S159N | P35659 | protein_coding | tolerated(0.43) | benign(0) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| DEK | SNV | Missense_Mutation | novel | c.524N>G | p.Leu175Arg | p.L175R | P35659 | protein_coding | deleterious(0) | probably_damaging(0.963) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| DEK | deletion | Frame_Shift_Del | novel | c.1113delN | p.Glu372SerfsTer2 | p.E372Sfs*2 | P35659 | protein_coding | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| DEK | deletion | Frame_Shift_Del | c.31delG | p.Glu11ArgfsTer53 | p.E11Rfs*53 | P35659 | protein_coding | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
| DEK | deletion | Frame_Shift_Del | c.773delN | p.Lys258ArgfsTer20 | p.K258Rfs*20 | P35659 | protein_coding | TCGA-AG-A02N-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Chemotherapy | folinic | CR |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |